Lyell Immunopharma announces 1-for-20 reverse stock split effective May 30, 2025

Lyell Immunopharma, Inc.

Reverse split at 1-for-20 ratio; effective 5:00 p.m. ET on May 30, 2025.
Common stock begins split-adjusted trading on Nasdaq June 2, 2025.
Proportionate adjustments to stock options, RSUs, and shares reserved under equity plans.
Pre-split shares outstanding: ~296.2M; post-split: ~14.8M (subject to fractional cash-out).
New CUSIP number: 55083R203; no change in par value or proportional ownership.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.